FDA+ guidance roundup: Benefit-risk assessments, RWE to support regulatory decision-making, and more
The FDA on Wednesday unloaded six new draft and final guidance documents across a range of topics, including two new drafts, both thanks to the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
